Bioimag ceases its activity. See at the News and announce


Tissue regeneration requires remodeling mediated by enzymatic activity. This regeneration is especially important for the next generation of heart valves, bone and soft tissue implants, among other products, where the regeneration of the implanted matrix is critical for product success.

It is currently impossible, using existing techniques, to determine enzymatic activity in vivo using non-invasive techniques. In vivo enzymatic activity is currently estimated by laboratory analysis of tissue extracts obtained surgically through biopsies, which proves highly problematic for heart valves.

Our engineered biomaterial enables the non-invasive detection of these target enzymes, yielding previously unavailable information that can predict the future state of heart valve replacements up to years in advance and will reduce the number of unnecessary replacements.

Collagenase class I

Our Vision

Visualize and predict the outcome of surgical treatments and implants by non invasive imaging. Our primary focus is to produce and design functionalized biomaterials that allow non-invasive monitoring of disease and fate of tissues in vivo, improving patient quality of life, reducing risks and saving costs. In doing so we intend to accelerate the development of regenerative therapies based in tissue engineering.

Simulated MRI visualization of proteolytic activity at a knee before  and after its occurs at left and right sides respectively


Bioimag's exclusive technology combines nanomagnetism, tissue engineering and medical imaging. Our current products in development can determine specific enzymatic activity that can be integrated in regenerative heart valves, bone grafts and dermal replacements. Our technology enables monitoring the enzymatic activity and the processes in vivo by a non-invasive and non-destructive method that can be performed multiple times so that doctors can gain a greater understanding of what is happening inside of their patients.